Ignite Proteomics
Ignite Proteomics, a Golden, Colorado-based precision oncology company, was acquired by Aditxt in 2026 to address therapy selection challenges in cancer care.
Profile
Ignite Proteomics provides functional proteomics testing to help oncologists select the most effective cancer treatments by measuring protein activation in tumors.
Ignite Proteomics, a Golden, Colorado-based precision oncology company, was acquired by Aditxt in 2026 to address therapy selection challenges in cancer care. Founded to leverage functional proteomics, the company operates a CLIA-certified lab and has established Medicare reimbursement for its tests at approximately $2,200 per test. Ignite's Reverse Phase Protein Array (RPPA) platform measures protein expression and activation, providing insights beyond genomic testing alone.
This approach is particularly relevant for antibody-drug conjugates (ADCs) and immunotherapies, where functional protein targets are critical. The company launched a 10,000-patient oncology registry in 2026, expected to generate $13 million in revenue, focusing on metastatic cancer patients with limited therapeutic options. Ignite's technology has been validated in studies, such as one published in the British Journal of Cancer, demonstrating its superiority in predicting breast cancer therapy response. The global cancer profiling market, estimated at $14 billion, presents a significant opportunity for Ignite, which targets a $3 billion serviceable market among patients eligible for ADC therapies.
Who buys this
- Oncologists and healthcare providers seeking precision oncology tools
- Biopharma companies developing targeted cancer therapies
- Molecular tumor boards integrating functional proteomics into decision-making
- Medicare and other insurers reimbursing for diagnostic tests
Strengths and what to watch
Strengths
- CLIA-certified laboratory with established Medicare reimbursement pathway
- Proprietary RPPA platform validated in clinical studies for predicting therapy response
- Strategic acquisition by Aditxt providing resources for scaling commercial operations
Watch for
- Dependence on Medicare reimbursement, which could be subject to policy changes
- Competition from established genomic testing companies expanding into proteomics
- Execution risk in scaling the 10,000-patient registry and integrating into clinical workflows
Recent moves
Key Information
- Founded
- 2024
- Headquarters
- Golden, Colorado
Frequently Asked Questions
What is functional proteomics in cancer treatment?
Functional proteomics analyzes protein activation in tumors to guide therapy selection. Ignite Proteomics' RPPA platform measures protein expression patterns, providing oncologists actionable data beyond genetic tests. This approach is particularly valuable for antibody-drug conjugates and immunotherapies where protein targets determine treatment efficacy. (47 words)
How does Ignite Proteomics' test help choose cancer therapies?
Ignite's CLIA-certified test measures protein activation states in tumors, identifying which pathways are driving cancer growth. Studies show it predicts therapy response better than genomic testing alone, especially for metastatic patients with limited options. Medicare reimburses the $2,200 test for qualifying cases. (48 words)
What is the RPPA platform used by Ignite Proteomics?
Reverse Phase Protein Array (RPPA) is Ignite's proprietary technology that quantitatively measures hundreds of phosphorylated proteins from tumor samples. Validated in studies like their British Journal of Cancer publication, it reveals functional protein networks influencing treatment response in breast and other cancers. (46 words)
Who acquired Ignite Proteomics and why?
Aditxt acquired Ignite Proteomics in 2026 to address therapy selection challenges in precision oncology. The acquisition provides resources to scale Ignite's 10,000-patient registry and commercialize their proteomic testing platform, targeting a $3 billion market for ADC and immunotherapy selection. (45 words)
Is Ignite Proteomics' test covered by insurance?
Yes, Ignite has established Medicare reimbursement at approximately $2,200 per test. Their CLIA-certified lab meets regulatory requirements for coverage, making the functional proteomics test accessible to oncologists treating eligible cancer patients, particularly those exploring targeted therapies. (42 words)
What cancers is Ignite Proteomics' test used for?
Initially validated in breast cancer, Ignite's platform applies to cancers where protein activation drives progression, especially cases considering antibody-drug conjugates or immunotherapies. Their 10,000-patient registry focuses on metastatic cancers with limited therapeutic options, expanding clinical evidence across tumor types. (47 words)
Sources
- www.stocktitan.net — 10,000-patient oncology registry and $13 million revenue projection
- www.nasdaq.com — Acquisition by Aditxt and market opportunity details
- www.biospace.com — Clinical validation of RPPA platform in breast cancer
- igniteproteomics.com — Company overview and product information